Article ID Journal Published Year Pages File Type
6088787 Digestive and Liver Disease 2014 6 Pages PDF
Abstract

BackgroundIn prior studies, pregabalin reduced rectal or colonic pain in patients with irritable bowel syndrome and healthy adults, suggesting reduction of afferent function.AimTo assess effects of pregabalin on colonic compliance, sensory and motor functions in patients with constipation-predominant irritable bowel syndrome.MethodsIn a pilot, double-blind, placebo-controlled, parallel-group study, we tested oral pregabalin, 200 mg, in 18 patients with constipation-predominant irritable bowel syndrome. With a barostatically controlled polyethylene balloon in the left colon, we assessed sensation thresholds and colonic compliance using ascending method of limits, sensation ratings over 4 levels of distension, fasting and postprandial colonic tone and phasic motility. Analysis of covariance (adjusted for the corresponding pre-drug response) was used to compare placebo and pregabalin. After 45% participants completed studies, we conducted an interim analysis to assess the conditional power to detect pre-specified treatment effects given the observed variation and treatment group differences based on the planned sample size for the trial.ResultsPregabalin did not significantly affect colonic compliance, sensation thresholds, sensation ratings, fasting or postprandial tone or motility index. The study was stopped for futility to detect an effect on visceral pain with the planned design and sample size.ConclusionPregabalin, 200 mg, might not reduce distension-related colonic pain in constipation-predominant irritable bowel syndrome patients.

Related Topics
Health Sciences Medicine and Dentistry Endocrinology, Diabetes and Metabolism
Authors
, , , , ,